Baird lowered the firm’s price target on Bluebird Bio to $7 from $10 and keeps an Outperform rating on the shares after the FDA approved the company’s sickle cell disease cell therapy. The analyst says concerns surrounding pricing and label dynamics are overdone. The firm continues to believe Lyfgenia will see uptake in a segment of patients but it reduced the price target to reflect the risks surrounding near-term dilution and the potential for incremental commercial headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- CRISPR Therapeutics (NASDAQ:CRSP) Tanks after Analyst Downgrade
- Bluebird Bio price target lowered by $2 at Wedbush, here’s why
- Bluebird presents updated data from gene therapy program in TDT beta-thalassemia
- Bluebird Bio announces efficacy, safety HRQoL data from sickle cell studies
- Bluebird sinks after Lyfgenia gets boxed warning, review voucher denied
